The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Han-yu, Zheng, Hui-min, Xia, Cheng, Li, Xiang, Wang, Gang, Zhao, Tong, Cui, Xiao-nan, Wang, Ruo-yu, Liu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957335/
https://www.ncbi.nlm.nih.gov/pubmed/35345394
http://dx.doi.org/10.2147/OTT.S333233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957335/
https://www.ncbi.nlm.nih.gov/pubmed/35345394
http://dx.doi.org/10.2147/OTT.S333233

Ejemplares similares